Interruption Of Anti-Thrombotic Therapies And Risk Of Post-Colonoscopy Thromboembolic Events: A Real-World Cohort Study

Yan Kiu Li,Ka Shing Cheung,Chuan-guo Guo,Kevin SH. Liu,Wai K. Leung
DOI: https://doi.org/10.1016/j.cgh.2022.09.021
IF: 13.576
2022-09-27
Clinical Gastroenterology and Hepatology
Abstract:Background and Aim Although anti-thrombotic agents could increase the risk of post-polypectomy bleeding, interruption of these agents also increases the risk of thromboembolism (TE). We assessed the risks of post-colonoscopy TE events and their association with the interruption of anti-thrombotic agents. Method This was a retrospective cohort study including consecutive patients undergoing colonoscopy between January 2016 and March 2021. We determined the rates of post-colonoscopy TE events in patients taking various anti-thrombotic agents (with or without interruption), and in different patient groups according to indications for colonoscopy, underlying TE and bleeding risks. Results Of the 6,220 patients, 1,755 (28.2%) were on anti-thrombotic. Overall, 20 patients (0.32%) developed TE events, and 25 (0.80%) of 3134 patients with polypectomy experienced major episodes of bleeding. There were 6 (0.1%) deaths related to TE events and all were on anti-thrombotic agents. Highest rates of TE events were observed in patients on dual anti-platelet therapy (4.65%; adjusted odds ratio [aOR] 28.0, 95% CI 3.77-142.1) and clopidogrel (2.78%; aOR 12.2, 95% CI 2.10-57.0), as compared to 0.11% among those not on anti-thrombotic. Stopping ≥2 anti-thrombotic agents (4.55%; aOR 22.5, 95% CI 1.09-158.0), or stopping monotherapy with clopidogrel (3.06%; aOR 15.5, 95%CI 2.86-69.6), warfarin (1.33%; aOR 6.96, 95%CI 1.14-33.5) or direct acting oral anticoagulants (DOAC) (0.87%; aOR 6.23, 95%CI 1.22-26.8) were all associated with higher risk of TE events. Patients with underlying high TE risk (aOR 16.8, 95% CI 6.33-46.6) were associated with higher post-colonoscopy TE events. Conclusion Temporary interruption of anti-thrombotic agents, particularly stopping ≥2 agents, clopidogrel, warfarin or DOAC was associated with higher post-colonoscopy TE events and even death, particularly in high risk patients.
gastroenterology & hepatology
What problem does this paper attempt to address?